A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2013-2020

ABSTRACT

This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy. In Parts B, C, and D, participants with advanced non-small cell lung cancer (NSCLC) will receive pembrolizumab in combination with either cisplatin/pemetrexed or carboplatin/pemetrexed (Part B); with either carboplatin/paclitaxel or carboplatin/nab-paclitaxel (Part C); or with ipilimumab (Part D) by non-random assignment to assess the safety and tolerability of the combination therapy. In Part E, participants with untreated Extensive-disease (ED) Small Cell Lung Cancer (SCLC) will receive pembrolizumab in combination with either cisplatin/etoposide, carboplatin/etoposide, or cisplatin/etoposide with prophylactic use of granulocyte colony-stimulating factor (lasting G-CSF [pegfilgrastim]) by non-random assignment to assess the safety and tolerability of the combination therapy. More... »

URL

https://clinicaltrials.gov/show/NCT01840579

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy. In Parts B, C, and D, participants with advanced non-small cell lung cancer (NSCLC) will receive pembrolizumab in combination with either cisplatin/pemetrexed or carboplatin/pemetrexed (Part B); with either carboplatin/paclitaxel or carboplatin/nab-paclitaxel (Part C); or with ipilimumab (Part D) by non-random assignment to assess the safety and tolerability of the combination therapy. In Part E, participants with untreated Extensive-disease (ED) Small Cell Lung Cancer (SCLC) will receive pembrolizumab in combination with either cisplatin/etoposide, carboplatin/etoposide, or cisplatin/etoposide with prophylactic use of granulocyte colony-stimulating factor (lasting G-CSF [pegfilgrastim]) by non-random assignment to assess the safety and tolerability of the combination therapy.", 
    "endDate": "2020-04-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01840579", 
    "keywords": [
      "I study", 
      "advanced solid tumor", 
      "platinum", 
      "immunotherapy", 
      "small cell", 
      "Small Cell Lung Carcinoma", 
      "cohort", 
      "safety", 
      "tolerability", 
      "monotherapy", 
      "Non-Small-Cell Lung Carcinoma", 
      "Paclitaxel", 
      "ipilimumab", 
      "random assignment", 
      "combination therapy", 
      "disease", 
      "prophylactic use", 
      "Granulocyte Colony-Stimulating Factor", 
      "CSF"
    ], 
    "name": "A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01840579"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00014.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417993.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2013-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s10637-016-0347-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032912726", 
          "https://doi.org/10.1007/s10637-016-0347-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-016-0347-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032912726", 
          "https://doi.org/10.1007/s10637-016-0347-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01840579"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01840579'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01840579'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01840579'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01840579'


 

This table displays all metadata directly associated to this object as RDF triples.

42 TRIPLES      16 PREDICATES      35 URIs      28 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01840579 schema:about anzsrc-for:3142
2 schema:description This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy. In Parts B, C, and D, participants with advanced non-small cell lung cancer (NSCLC) will receive pembrolizumab in combination with either cisplatin/pemetrexed or carboplatin/pemetrexed (Part B); with either carboplatin/paclitaxel or carboplatin/nab-paclitaxel (Part C); or with ipilimumab (Part D) by non-random assignment to assess the safety and tolerability of the combination therapy. In Part E, participants with untreated Extensive-disease (ED) Small Cell Lung Cancer (SCLC) will receive pembrolizumab in combination with either cisplatin/etoposide, carboplatin/etoposide, or cisplatin/etoposide with prophylactic use of granulocyte colony-stimulating factor (lasting G-CSF [pegfilgrastim]) by non-random assignment to assess the safety and tolerability of the combination therapy.
3 schema:endDate 2020-04-01T00:00:00Z
4 schema:keywords CSF
5 Granulocyte Colony-Stimulating Factor
6 I study
7 Non-Small-Cell Lung Carcinoma
8 Paclitaxel
9 Small Cell Lung Carcinoma
10 advanced solid tumor
11 cohort
12 combination therapy
13 disease
14 immunotherapy
15 ipilimumab
16 monotherapy
17 platinum
18 prophylactic use
19 random assignment
20 safety
21 small cell
22 tolerability
23 schema:name A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.
24 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01840579
25 schema:sdDatePublished 2019-03-07T15:24
26 schema:sdLicense https://scigraph.springernature.com/explorer/license/
27 schema:sdPublisher Na254794fab5749209084baa1cb0626e1
28 schema:sponsor https://www.grid.ac/institutes/grid.417993.1
29 schema:startDate 2013-04-01T00:00:00Z
30 schema:subjectOf sg:pub.10.1007/s10637-016-0347-6
31 schema:url https://clinicaltrials.gov/show/NCT01840579
32 sgo:license sg:explorer/license/
33 sgo:sdDataset clinical_trials
34 rdf:type schema:MedicalStudy
35 Na254794fab5749209084baa1cb0626e1 schema:name Springer Nature - SN SciGraph project
36 rdf:type schema:Organization
37 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
38 rdf:type schema:DefinedTerm
39 sg:pub.10.1007/s10637-016-0347-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032912726
40 https://doi.org/10.1007/s10637-016-0347-6
41 rdf:type schema:CreativeWork
42 https://www.grid.ac/institutes/grid.417993.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...